U.S. Companion Animal Health Market Size, Share, Price, Trends, Forecast 2024-2032

U.S. Companion Animal Health Market Size And Forecast

U.S. Companion Animal Health Market size was valued at USD 5.46 Billion in 2020 and is projected to reach USD 7.37 Billion by 2028, growing at a CAGR of 6.18% from 2021 to 2028.

The U.S. is primarily driven by the increasing adoption of companion animals in the country, as well as increased awareness of animal diagnostics among pet owners. The most popular companion animals are cats and dogs. According to the American Housing Survey conducted by the United States Census Bureau in 2018/2019, 49.0 percent of households have at least one pet. Growing pet ownership has heightened concerns about their health, propelling the market forward. The introduction of artificial intelligence (AI) has enabled early and accurate diagnosis, presenting promising growth prospects in the coming years. PetSensus and Insilco Medicine partnered in April 2019 to provide animal longevity through their biomedical data platform.

The rising incidence of cancer, particularly in dogs, is expected to propel the market forward. According to the Animal Cancer Foundation, cancer affects 65 million dogs and 32 million cats in the United States. According to the American Veterinary Medical Association in 2019, dogs are more likely to develop malignant neoplasia (tumor) and lymphoma. The incidence of zoonotic and food-borne diseases will be a potential concern to the health of pet animals, increasing pet/companion ownership, growing healthcare concerns of pets, and rising demand for improved nutrition are all driving the U.S. Companion Animal Health Market.

U.S. Companion Animal Health Market Definition

Companion animals provide companionship and protect people’s homes and offices. The market is growing due to a variety of animal diseases and their transmission to humans via their products and companionship. Companies are putting more emphasis on research and technological advancement to develop better pharmaceutical and vaccine products for their existing and newly diagnosed dialysis patients.

To gain expertise in developing new active pharmaceutical ingredients/drugs, the U.S. Companion Animal Health Market has seen some significant mergers and acquisitions. Most blockbuster drugs are now off-patent, so the market for branded generic drugs has a lot of potentials. In the next 15-20 years, increased investment in R&D to develop drugs will pay off handsomely for companion animal healthcare companies.

Dogs, cats, horses, rabbits, ferrets, birds, guinea pigs, and a few other small mammals, reptiles, and fish are all suitable companion animals. Domestic-bred farm animals can be kept as companions in places where they are allowed to be kept legally and responsibly. Dogs and cats are the most common, but we also share our homes and lives with horses, birds, rabbits, goats, gerbils, snakes, rats, mice, fish, amphibians, and other animals. Companion animals are frequently our best friends, confidants, and family members.

U.S. Companion Animal Health Market Overview

Pets save lives by protecting people, property, and homes, resulting in an increase in pet ownership around the world. Pet ownership is unquestionably increasing, which is helping to drive the U.S. Companion Animal Health Market forward. Furthermore, the market’s growth rate is bolstered by the growing urbanized population, rising prevalence of animal health care, and the provision of high-quality food products. The expansion of veterinary hospitals in both private and public organizations is also boosting the market. The U.S. Companion Animal Health Market is also fueled by rising pharmaceutical industry investments aimed at improving the quality of drugs and vaccines.

An increase in disposable income and a recent trend are driving up the number of companion animals, and expanding pet insurance options in many countries are driving up the demand for companion animal health. The high cost of animal diagnosis in the event of a product recall, as well as an increase in complication issues and a lack of standardization, are slowly stifling market demand. In addition, a lack of knowledge about drug dosage levels and fluctuations in raw material availability is driving up the price of final products, impeding the U.S. Companion Animal Health Market growth.

In the early years of 2021, the COVID-19 epidemic began spreading around the world, infecting millions of people and prompting major governments around the world to declare it a public health emergency. Many market have been harmed by the emerging COVID-19 outbreak. The outbreak of Coronavirus disease (COVID-19) posed a major challenge to the animal medicine industry, as trade restrictions disrupted supply chains and demand fell as a result of government shutdowns. Companion animal diseases are more likely to be transmitted to humans. Dog and cat bites cause a variety of infections in humans.

Other diseases found in pets include neoplasia, distemper, parvovirus, leukemia, panleukopenia, and viral rhinotracheitis. Because many of these diseases are fatal even when treated properly, the majority of pet owners have their animals vaccinated regularly. To protect against such diseases, both pets and humans need to be vaccinated. The growing demand for prophylactic vaccines will propel the segment forward. Restriction by regulatory bodies that hurt antibiotic sales, soaring costs, and increasing regulations on animal testing has prevented several healthcare companies from manufacturing new advanced drugs are among the restraints that will slow the market’s growth.

U.S. Companion Animal Health Market: Segmentation Analysis

The U.S. Companion Animal Health Market is Segmented on the basis of Animal Type, Product, Distribution Channel, And Geography.

U.S. Companion Animal Health Market, By Animal Type

• Dog• Cat• Equine• Others

Based on Animal Type, The market is segmented into Dog, Cat, Equine, and Others.

U.S. Companion Animal Health Market, By Product

• Vaccines• Pharmaceuticalso OTCo Prescription• Feed Additives• Diagnostics• Others

Based on Product, The market is segmented into Vaccines, Pharmaceuticals, Feed Additives, Diagnostics, and Others.

U.S. Companion Animal Health Market, By Distribution Channel

• Retail• E-commerce• Hospital Pharmacy

Based on Distribution Channel, The market is segmented into Retail, E-commerce, and Hospital Pharmacy.

U.S. Companion Animal Health Market, By Geography

• North America• U.S

Based on Regional Analysis, The U.S. Companion Animal Health Market is classified into  North America, U.S. The United States is the largest market for companion animal health, with growth attributed to a diverse range of animal-care products, strict government regulations, and a growing focus on animal health. According to the American Pet Products Association, overall household pet ownership increased to 68% in 2016, up from 54% in 2009. Europe is the second-largest market, owing to an increase in pet ownership as a result of government tax breaks, which has boosted the market’s growth in the region.

Key Players

The “U.S. Companion Animal Health Market” study report will provide a valuable insight with an emphasis on U.S. market including some of the major players such as Bayer AG, Elanco Animal Health, Merck & Co., Merial, Virbac, Vetoquinol SA, Zoetis Inc., Novartis Animal Health, Inc., Sanofi Animal Health, Inc., Bionic he Animal Health Canada.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players.

Key Developments

Partnerships, Collaborations and Agreements

• September 9, 2020, Bayer is working with Recursion to improve digital drug discovery and develop new therapies for fibrotic diseases.

• May, 2021. EVAH Corp has announced the signing of four contracts with Elanco Animal Health Incorporated to acquire and develop animal health technologies. EVAH is a biotechnology company that specialises in the development of biologicals to aid in the prevention of bacterial diseases in food animals as well as microbiome solutions for growth performance.

• June 24, 2021. MicroMGx and Elanco have announced a research collaboration agreement to investigate animal-health promoting microorganisms.

Mergers and Acquisitions

• June of 2020. Bayer AG has agreed to pay up to $4 billion for Asklepios BioPharmaceutical Inc., bolstering its pharma division with experimental gene therapies before patents on some key drugs expire.

• August 2020. Elanco has completed its purchase of Bayer Animal Health. The $6.89 billion cash and stock deal brings together two major producers of drugs for pets and livestock.

Product Launches and Product Expansions

• March 2021 Elanco is expanding its anticoccidial portfolio. The company is launching three antibiotic-free intestinal integrity products.

• March 2021. Merck accelerates plans for European expansion of single-use products critical to the manufacture of vaccines and life-saving therapies.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.